Sionna Therapeutics, Inc. (SION)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch SION
See up to 3 months of SION. The 7-day demo opens the 1M and 3M ranges and puts SION on your watchlist.
Start 7-day demoLatest SION insider trades
About Sionna Therapeutics, Inc. (SION)
Sionna Therapeutics, Inc. files with the SEC under CIK 0002036042 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
SION Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 3,448,811 | $21.84M |
| Grant or award | 12 | 1,329,232 | |
| Derivative transaction | 4 | 860,380 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
SION insider transactions (Form 4)
5956 Form 4 filings on record, the earliest from Jul 1, 2025, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. - Director | Open-market sale | Common Stock | 3,415,011 | $6.32 | $21.58M | |
| RA CAPITAL MANAGEMENT, L.P. - Director | Open-market sale | Common Stock | 33,800 | $7.46 footnote F3 | $252K | |
| ||||||
| Elena Ridloff - Officer | Grant or award | Common Stock | 47,269 | $0.00 | - | |
| Elena Ridloff - Officer | Grant or award | Common Stock | 47,268 | $0.00 | - | |
| Elena Ridloff - Officer | Grant or award | Non-Qualified Stock Option (right to buy) | 165,440 | $0.00 footnote F4 | - | |
| Elena Ridloff - Officer | Derivative | Non-Qualified Stock Option (right to buy) | 165,440 | $0.00 footnote F4 | - | |
| ||||||
| Charlotte McKee - Officer | Grant or award | Common Stock | 50,000 | $0.00 | - | |
| Charlotte McKee - Officer | Grant or award | Common Stock | 50,000 | $0.00 | - | |
| Charlotte McKee - Officer | Grant or award | Non-Qualified Stock Option (right to buy) | 155,700 | $0.00 footnote F4 | - | |
| Charlotte McKee - Officer | Derivative | Non-Qualified Stock Option (right to buy) | 155,700 | $0.00 footnote F4 | - | |
| ||||||
| Jennifer Fitzpatrick - Officer | Grant or award | Common Stock | 28,133 | $0.00 | - | |
| Jennifer Fitzpatrick - Officer | Grant or award | Common Stock | 28,132 | $0.00 | - | |
| Jennifer Fitzpatrick - Officer | Grant or award | Non-Qualified Stock Option (right to buy) | 103,140 | $0.00 footnote F4 | - | |
| Jennifer Fitzpatrick - Officer | Derivative | Non-Qualified Stock Option (right to buy) | 103,140 | $0.00 footnote F4 | - | |
| ||||||
| Michael Cloonan - Officer | Grant or award | Common Stock | 109,025 | $0.00 | - | |
| Michael Cloonan - Officer | Grant or award | Common Stock | 109,025 | $0.00 | - | |
| Michael Cloonan - Officer | Grant or award | Non-Qualified Stock Option (right to buy) | 436,100 | $0.00 footnote F4 | - | |
| Michael Cloonan - Officer | Derivative | Non-Qualified Stock Option (right to buy) | 436,100 | $0.00 footnote F4 | - | |
| ||||||
 Peter A. Thompson - Director | Open-market sale | Common Stock | 85,918 footnote F1 | $44.86 | $3.85M | |
| ||||||
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 85,918 footnote F1 | $44.86 | $3.85M | |
| ||||||
| Jennifer Fitzpatrick - Officer | Option exercise | Common Stock | 10,250 | $6.11 | $63K | |
| Jennifer Fitzpatrick - Officer | Open-market sale | Common Stock | 10,250 | $43.60 footnote F2 | $447K | |
| Jennifer Fitzpatrick - Officer | Option exercise | Non-Qualified Stock Option (right to buy) | 10,250 | $0.00 | - | |
| ||||||
| Peter A. Thompson - Director | Open-market sale | Common Stock | 115,844 footnote F1 | $45.50 | $5.27M | |
| ||||||
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 115,844 footnote F1 | $45.50 | $5.27M | |
| ||||||
| Laurie Stelzer - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
 Joanne L. Viney - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
| Peter A. Thompson - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
| RA CAPITAL MANAGEMENT, L.P. | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
| Marcella K. Ruddy - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
| Joshua Resnick - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
| Harold Edward Fleming - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
| Paul J. Clancy - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
 Bruce Booth - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 17,340 | $0.00 | - | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 101 footnote F1 | $44.49 | $4K | |
| ||||||
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 101 footnote F1 | $44.49 | $4K | |
| ||||||
| Peter A. Thompson - Director | Open-market sale | Common Stock | 48,546 footnote F1 | $44.61 | $2.17M | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 59,767 footnote F1 | $44.58 | $2.66M | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 184,639 footnote F1 | $46.22 | $8.53M | |
| ||||||
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 48,546 footnote F1 | $44.61 | $2.17M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 59,767 footnote F1 | $44.58 | $2.66M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 184,639 footnote F1 | $46.22 | $8.53M | |
| ||||||
| Peter A. Thompson - Director | Open-market sale | Common Stock | 52,397 footnote F1 | $44.68 | $2.34M | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 2,948 footnote F1 | $44.52 | $131K | |
| ||||||
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 52,397 footnote F1 | $44.68 | $2.34M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 2,948 footnote F1 | $44.52 | $131K | |
| ||||||
| Peter A. Thompson - Director | Open-market sale | Common Stock | 47,814 footnote F1 | $44.51 | $2.13M | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 235,863 footnote F1 | $44.64 | $10.53M | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 226,906 footnote F1 | $45.34 | $10.29M | |
| ||||||
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 47,814 footnote F1 | $44.51 | $2.13M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 235,863 footnote F1 | $44.64 | $10.53M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 226,906 footnote F1 | $45.34 | $10.29M | |
| ||||||
| Jennifer Fitzpatrick - Officer | Option exercise | Common Stock | 10,250 | $6.11 | $63K | |
| Jennifer Fitzpatrick - Officer | Open-market sale | Common Stock | 10,250 | $33.86 footnote F2 | $347K | |
| Jennifer Fitzpatrick - Officer | Option exercise | Non-Qualified Stock Option (right to buy) | 10,250 | $0.00 | - | |
| ||||||
| Peter A. Thompson - Director | Open-market sale | Common Stock | 1,890 | $44.57 | $84K | |
| Peter A. Thompson - Director | Open-market sale | Common Stock | 29,063 | $44.58 | $1.30M | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 1,890 | $44.57 | $84K | |
| ORBIMED ADVISORS LLC - Director | Open-market sale | Common Stock | 29,063 | $44.58 | $1.30M | |
Item 2.05, 5.02, 8.01, 9.01
Item 8.01, 9.01
Item 2.02, 9.01
Item 5.07
Recent SION Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| RA Capital Healthcare Fund, L.P. | Director, 10% Stockholder | 3,448,811 | $21.83M | View on EDGAR | |
| - | - | - |
SION insider trading FAQ
What is the latest insider trade for SION?
Sionna Therapeutics, Inc. (SION) had 5 insider filings in the last 90 days, with the most recent on 2026-09-21. The full record for SION runs to 56 Form 4 filings, the earliest from 2025-07-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying SION stock?
No insider purchases of SION were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling SION stock?
2 insider sales of SION were filed in the last 90 days, totaling $21.84M.
Where can I see SION SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects SION Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - RA CAPITAL MANAGEMENT, L.P. view on EDGAR
- - Elena Ridloff view on EDGAR
- - Charlotte McKee view on EDGAR
- - Jennifer Fitzpatrick view on EDGAR
- - Michael Cloonan view on EDGAR
- - Peter A. Thompson view on EDGAR
- - ORBIMED ADVISORS LLC view on EDGAR
- - Jennifer Fitzpatrick view on EDGAR
- - Peter A. Thompson view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where SION's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow SION with a 7-day demo
- SION on your watchlist
- Every SION Form 4 filing on record
- Up to 3 months of SION price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
